CR

Chand Rameshbhai Kanabar

Active Director Director DIN 10706050
DIN 10706050 First appointment Jul 2024 Primary industry General Business
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since Jul 2024
Shareholding value •••• Premium profile

About Chand Rameshbhai Kanabar

Data last updated:

Chand Rameshbhai Kanabar has 2 years in corporate governance. Holds Director role. Currently with 5 companies, including Riddhi Display Equipments Limited and Accretion Pharmaceuticals Limited. Formerly with 1 company, such as Shining Tools Limited. Engaged in General Business. Contributes to corporate operations. The 4 current companies with reported revenue have a combined latest revenue of ₹135 Cr; the largest is Accretion Pharmaceuticals Limited at ₹57.47 Cr (FY 2025).

DIN 10706050
Primary Designation Director
First Appointment 15 Jul 2024
Oldest Company Age 20 yrs
Largest company Accretion Pharmaceuticals Limited · ₹57.47 Cr (FY 2025)
Combined revenue ₹135 Cr across 4 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Accretion Pharmaceuticals Limited L21004GJ2023PLC146545
Director19 Apr 20252023₹57.47 Cr (FY 2025)Active
Curis Lifesciences Limited L24230GJ2016PLC086559
Director06 Nov 20242016₹35.98 Cr (FY 2024)Active
Riddhi Display Equipments Limited U29300GJ2006PLC047501
Director16 Dec 20242006₹25.09 Cr (FY 2025)Active
Accretion Nutraveda Limited L24290GJ2021PLC121216
Director08 May 20262021₹16.01 Cr (FY 2025)Active
Director15 Jul 20242024–Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Shining Tools Limited L29220GJ2013PLC074803
Director07 Nov 20242013₹10.60 Cr (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Riddhi Display Equipments Limited
Accretion Pharmaceuticals Limited
Curis Lifesciences Limited
Golden Sparrow Consultancy Private Limited
Premium access

Shareholding and investment profile for Chand Rameshbhai Kanabar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Chand Rameshbhai Kanabar

Chand Rameshbhai Kanabar has 2 years in corporate governance. Holds Director role. Currently with 5 companies, including Riddhi Display Equipments Limited and Accretion Pharmaceuticals Limited. Formerly with 1 company, such as Shining Tools Limited. Engaged in General Business. Contributes to corporate operations. The 4 current companies with reported revenue have a combined latest revenue of ₹135 Cr; the largest is Accretion Pharmaceuticals Limited at ₹57.47 Cr (FY 2025).

Chand Rameshbhai Kanabar is associated with 5 companies as Director, including Accretion Pharmaceuticals Limited (₹57.47 Cr), Curis Lifesciences Limited (₹35.98 Cr), Riddhi Display Equipments Limited (₹25.09 Cr).

Chand Rameshbhai Kanabar has expertise in General Business.

Chand Rameshbhai Kanabar has 2 years in corporate governance.

By reported revenue, the largest current company of Chand Rameshbhai Kanabar is Accretion Pharmaceuticals Limited, with revenue of ₹57.47 Cr (FY 2025).

The 4 current companies of Chand Rameshbhai Kanabar that report revenue have a combined latest revenue of ₹135 Cr.

Chand Rameshbhai Kanabar currently holds positions at 5 companies: Accretion Pharmaceuticals Limited (₹57.47 Cr), Curis Lifesciences Limited (₹35.98 Cr), Riddhi Display Equipments Limited (₹25.09 Cr), Accretion Nutraveda Limited (₹16.01 Cr), Golden Sparrow Consultancy Private Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available